Vaccine Therapies for Brain Tumors

Doctor review pending.

Therapeutic Vaccines for Glioblastoma and Other Brain Tumors

Last updated 4/27/25

Concept

Cancer vaccines train a patient's immune system to recognize tumor-specific antigens and mount a durable T-cell response that helps keep residual cancer in check. Unlike preventive vaccines, these therapeutic vaccines are given after diagnosis, usually alongside surgery, radiation and temozolomide.

Vaccine Classes

  • Tumor-lysate dendritic-cell vaccines - Autologous dendritic cells pulsed with the patient's own tumor lysate to present a broad repertoire of neoantigens (e.g., DCVax-L).
  • Peptide vaccines - Short synthetic peptides representing one or more tumor antigens mixed with an adjuvant (e.g., SurVaxM, ITI-1001).
  • mRNA vaccines - Lipid-nanoparticle mRNA encoding patient-specific neoantigens; early-phase GBM studies are recruiting (e.g., BNT-201 by BioNTech).

Representative Candidates

ProductPlatformTarget Antigen(s)Clinical Status
DCVax-L (Northwest Bio) Tumor-lysate dendritic cells Patient-specific neoantigens Phase 3 complete; marketing application under review by UK MHRA (2024)
SurVaxM (MimiVax) Peptide + Montanide + sargramostim Survivin (MHC I & II) Phase 2b randomized trial enrolling (SURVAXM-001)
NeoVax / ITI-1001 (Dana-Farber / Immunomic) Personalized peptide pool + Poly-ICLC Top 20 neoantigens per patient Phase 1 complete; combination trials planned
Gliovac (ERC-1671) Allogeneic + autologous tumor-lysate mix with GM-CSF + cyclophosphamide Heterogeneous whole-tumor antigens Phase 2 data; available in the US under Right-to-Try or single-patient IND

How They Are Used

  • Treatment window: Most protocols start 3-8 weeks after chemoradiation, once steroids are ≤2 mg/day dexamethasone.
  • Companion therapy: Vaccines are frequently paired with low-dose temozolomide, Poly-ICLC or checkpoint inhibitors to boost immunogenicity.
  • Dosing schedule: Typically injected every 2-4 weeks for 3-6 doses, followed by maintenance boosters every 2-3 months.

Key Research Highlights

Access and Availability

  • DCVax-L: Not commercially available. A Special Access Programme is open in the UK; contact Northwest Bio for details. No US expanded-access sites at present.
  • SurVaxM: Accessible only through the SURVAXM-001 multicenter trial in the US.
  • Gliovac: Available under the US Right-to-Try Act or single-patient IND; contact ERC Belgium or partner sites.
  • Personalized peptide or mRNA vaccines: Limited to early-phase trials at Dana-Farber, Penn, BioNTech, etc.

Frequently Asked Questions

Can I start a vaccine if I'm still on steroids?
High-dose steroids (>2 mg/day dex) blunt T-cell priming. Most studies require taper to ≤2 mg/day before the first dose.

How soon will it work?
Immune monitoring shows peak neoantigen-specific T cells by roughly week 12; radiographic responses usually lag 3-6 months.

What about cost?
Investigational vaccines are free in trials. Commercial pricing will be set after regulatory approval and insurer negotiations.



Our Terms of Use and Privacy Policy has changed.
Click HERE to read it!